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An increase in the number of preterm infants and a decrease in 
the gestational age at birth have resulted in an increase in the 
number of patients with significant bronchopulmonary dysplasia 
(BPD) and secondary pulmonary hypertension (PH). PH contributes 
significantly to the high morbidity and mortality in the BPD patients. 
Therefore, regular monitoring for PH by using echocardiography 
and B-type natriuretic peptide (BNP) or N-terminal-proBNP must 
be conducted in the BPD patients with greater than moderate 
degree to prevent PH and to ensure early treatment if PH is present. 
In the BPD patients with significant PH, multi-modality treatment, 
including treatment for correcting an underlying disease, oxygen 
supply, use of diverse selective pulmonary vasodilators (inhaled 
nitric oxide, inhaled prostacyclins, sildenafil, and endothelin-
receptor antagonist) and other methods, is mandatory.
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Introduction
Bronchopulmonary dysplasia (BPD) was first described by 
Northway et al. (1967) as a chronic lung disease of preterm infants 
who required oxygen supply and mechanical ventilation for acute 
respiratory distress
1). The introduction of prenatal steroid therapy, 
gentle ventilation techniques, exogenous surfactant treatment, and 
intensive treatment of patent ductus arteriosus have minimized 
severe lung injury and improved the survival rate in preterm infants 
over the 40 years since the introduction of the BPD concept. 
However, some infants with very low birth weight still develop 
BPD
2). The overall incidence of BPD, which is characterized by the 
need for oxygen at 36 weeks of gestation, is about 30% for infants 
with birth weight less than 1,000 g in the United States
3) and 
9.7% for infants with birth weight less than 1,500 g analyzed in a 
Korean multicenter study
4). 
Preterm infants with BPD usually have cardiovascular sequelae, 
such as pulmonary hypertension (PH), cor pulmonale with 
right ventricular (RV) hypertrophy, systemic hypertension, 
left ventricular hypertrophy, and development of systemic-to-
pulmonary collateral vessels
5). Among these cardiovascular 
sequelae, PH contributes significantly to the high morbidity and 
mortality in the BPD patients. Although little is known about the 
prevalence and mortality rate of PH, the prevalence of PH ranges 
from 8 to 25% and the mortality rate ranges from 14 to 50% in 
the BPD patients with PH
6-9). 
This review focuses on the precise evaluation of the severity of 
PH and the recent progress in the treatment of PH in the BPD 
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patients.
Development of PH in the BPD patients
According to the classification of PH by the symposium at Dana 
Point in 2008, BPD is considered to be a class 3 disorder, which 
is PH with lung disease and/or hypoxia
10) (Table 1). Although the 
exact pathophysiological characteristics of PH in the BPD patients 
is unknown, several mechanisms have been proposed. Abnormal 
lung circulation in the BPD patients, including both anatomical and 
physiologic abnormality, is related to the development of PH. The 
patients with BPD show reduction of small pulmonary arteries and 
an altered distribution of pulmonary arteries within the pulmonary 
interstitium
11), which cause reduction of alveolar–capillary surface 
area. This reduction in surface area causes impairment of gas 
exchange and increases the requirement for prolonged oxygen 
and ventilator treatment, which in turn, raise the risk for severe 
PH. These pulmonary vascular changes, which are characterized 
by decreased vascular growth and structure, in preterm infants 
also contribute to the abnormal cardiopulmonary sequelae of 
BPD
12). Physiologic abnormalities of lung circulation include 
increased vascular tone and reactivity, hypertensive remodeling, 
and decreased vascular growth
12, 13). Previous studies using cardiac 
catheterization have shown that even mild hypoxia causes marked 
elevation of pulmonary artery pressure in the patients, including 
preterm infants with BPD
14). To achieve normal gas exchange, the 
lung tissue must undergo continuous growth and maintenance of 
the complex system of airways and vessels. However, disruption of 
angiogenesis and inhibition of pulmonary vascular growth during 
a critical period of postnatal lung growth impairs pulmonary 
alveolarization, which contributes to BPD and increases the risk for 
PH
15). 
Systemic-to-pulmonary collateral vessels, including prominent 
bronchial arteries, also contribute to PH development in the 
BPD patients. Significantly large collateral vessels may result 
in significant shunt flow to the lung and cause pulmonary 
congestion, ultimately requiring more ventilatory support and 
medications
16). In some cases, patients showed improvement of 
PH after embolization of large collateral vessels and required less 
supplemental oxygen and ventilatory support
12).
Diagnosis of PH in the BPD patients
Early detection of PH may lead to earlier treatment with more 
aggressive respiratory support and cardiac medications, including 
pulmonary vasodilators, and other procedures to improve the 
outcome in the BPD patients. However, the diagnosis of PH in 
BPD patients is difficult because manifested symptoms and signs 
of PH may be subtle and may sometimes overlap with those of 
respiratory problems or infection. In this respect, screening of 
PH in the BPD patients is necessary to decrease morbidity and 
mortality from PH.
PH in the BPD patients is defined as a condition characterized 
by a mean pulmonary artery pressure greater than 25 mmHg 
and pulmonary capillary wedge pressure less than 15 mmHg 
on cardiac catheterization in the resting state
10). Cardiac cathe-
terization is the gold standard for the diagnosis of PH; however, 
since this procedure is very invasive and is not performed in all the 
centers with neonatal intensive care unit (NICU), other diagnostic 
tools are used for the evaluation of PH in the BPD patients. 
Electrocardiography (ECG) and echocardiography may be used as 
screening methods for PH in most centers with NICU. Although 
ECG can be easily performed, it is known to have low sensitivity 
and positive predictive value for the diagnosis of RV hypertrophy 
in the precordial leads reflecting PH. In a recent study, Puchaiski 
et al. also showed no significant relationship between ECG 
findings and echocardiographic estimation of pulmonary artery 
pressure
17). Therefore, serial echocardiography, in spite of its several 
Table 1. Clinical Classification of Pulmonary Hypertension (Dana Point 
in 2008)
1.  Pulmonary arterial hypertension
 1.1 Idiopathic
 1.2. Heritable
 1.3. Drugs and toxins induced
 1.4. Associated with 
  1.4.1. Connective tissue disease
  1.4.2. HIV infection
  1.4.3. Portal hypertension
  1.4.4. Congenital heart disease
  1.4.5. Schistosomiasis
  1.4.6. Chronic hemolytic anemia
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary
    Haemangiomatosis 
2. Pulmonary hypertension due to left heart disease
 2.1. Systolic dysfunction
 2.2. Diastolic dysfunction
 2.3. Valvular disease
3. Pulmonary hypertension due to lung diseases and/or hypoxia
 3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
 3.3. Other pulmonary diseases with mixed restrictive and 
        obstructive pattern
 3.4. Sleep-disordered breathing
 3.5. Alveolar hypoventilation disorders
 3.6. Chronic exposure to high altitude
 3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension
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limitations, is recommended as the main screening tool for PH in 
the BPD patients in many centers. In Seoul National University 
Children’s Hospital, we conduct monthly echocardiographic 
examination of the preterm infants with BPD in the NICU to 
screen for PH and of the follow-up patients with moderate to 
severe BPD in the cardiologic division after discharge from the 
hospital even though the patients did not have PH in the NICU. 
A report from Boston Children’s Hospital recommended that 
echocardiographic screening for PH should be conducted in 
preterm infants with BPD who meet any of the following criteria: (1) 
extreme prematurity (gestational age at birth of ≤25 weeks or birth 
weight of ≤600 g), (2) small for gestational age, (3) requirement for 
prolonged mechanical ventilatory support (duration depends on 
age), (4) oxygen requirement out of proportion to the severity of 
lung disease, or (5) persistent poor growth despite adequate caloric 
intake
8).
Estimated systolic pulmonary artery pressure can be derived 
from the tricuspid regurgitant (TR) jet flow, which if present, is 
measured by echocardiography by using the modified Bernoulli 
equation [systolic pulmonary artery pressure=4×(TR peak jet 
velocity)
2+right atrial pressure]
18). However, estimation of systolic 
pulmonary artery pressure may not be possible in all the patients. A 
recent study revealed that estimation of systolic pulmonary artery 
pressure was possible in only 61% of the young children with PH
19). 
In the absence of TR jet flow, other qualitative echocardiographic 
findings, including right atrial enlargement, RV hypertrophy 
and/or dilation, septal flattening, increased RV wall thickness, 
dilated main pulmonary artery, increased velocity of pulmonary 
valve regurgitation, and a short acceleration time of RV ejection 
into the pulmonary artery, can be used to detect PH; however, 
the sensitivity of these findings is questionable
10, 12). Among these 
qualitative echocardiographic findings, interventricular septal 
configuration is very useful for evaluating the severity of PH in 
the BPD patients. Systolic RV pressure can be graded according 
to the position of the interventricular septum: (1) <50% of the 
systemic systolic pressure if the interventricular septum appears 
round at end-systole, (2) 50-100% of the systemic systolic pressure 
if the septum shows flattening at end-systole, and (3) ≥100% of the 
systemic systolic pressure if the interventricular septum bows into 
the left ventricle at end-systole (Fig. 1)
20).
Another useful parameter for the evaluation of PH severity is 
biochemical marker. B-type natriuretic peptide (BNP) and N- 
terminal proBNP (NT-proBNP) are representatives of biomarker 
and showed good positive correlations with mean pulmonary 
artery pressure, pulmonary vascular resistance and mean right 
atrial pressure. BNP also showed good negative correlation with 
RV ejection fraction
21) even though normal value of children’s age 
is not known well until now through extensive studies
22). We have 
to be alert if the BPD patients with PH show high serum level or 
increasing level of BNP or NT-proBNP, because these parameters 
reflect disease status including severity.
In some centers, cardiac catheterization is generally recom-
mended to evaluate the severity of PH, to rule out unsuspected 
associated anatomic cardiac diseases, to define the presence of 
systemic-to-pulmonary collateral vessels, pulmonary venous 
obstruction, or left heart dysfunction, and to assess pulmonary 
vascular reactivity in patients who fail to respond to oxygen 
treatment alone
12).
Fig. 1. Interventricular septal configuration (IVS) for predicting the 
severity of pulmonary hypertension. (A), round IVS at end-systole, 
systolic right ventricular (RV) pressure is estimated to be less than 50% 
of the systemic systolic pressure. (B), flat IVS at end-systole, systolic 
RV pressure is estimated to be between 50 and 100% of the systemic 
systolic pressure. (C), IVS bowed into the left ventricle (LV) at end-
systole, systolic RV pressure is estimated to be greater than 100% of 
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Treatment of PH in the BPD patients
Most patients with PH showed gradual resolution of PH over the 
first year of life because the damaged lung recovered and normal 
alveolarization completed. However, because some BPD patients 
with severe PH could experience fatal right heart failure and other 
complications from PH
6-9), meticulous and aggressive treatment of 
PH in the BPD patients is mandatory. 
The basis of the treatment of PH in the BPD patients is to 
correct the underlying lung disease. These underlying conditions 
include chronic gastroesophageal reflux and aspiration, airway 
problems, such as laryngotracheomalacia, subglottic stenosis, and 
vocal cord palsy, and other conditions that cause intermittent 
or persistent hypoxia
12). In case of repairable anatomic lesions to 
contribute to the PH, aggressive correction should be performed 
because the reduced vascular surface area in the BPD patients 
may result in significant hemodynamic injury caused by even a 
relatively small increase of left-to-right blood shunt through the 
patent foramen ovale, atrial septal defect, patent ductus arteriosus, 
or even other systemic-to-pulmonary collateral vessels
12).
Oxygen supply is the mainstay of the medical treatment of PH in 
the BPD patients. Chronic hypoxia can induce pul  monary vascular 
constriction and aggravate PH, while sufficient oxygenation can be 
helpful in the recovery of damaged pulmonary tissue and normal 
growth of the lung. In this regard, oxygen saturation (SpO2) 
should be maintained at more than 93-95% in the patients with 
BPD
23). The oxygen supply should be discontinued when the SpO2 
is greater than 93~95% without oxygen supply. In particular, the 
BPD patients with PH should have an SpO2 in the mid-90%
24, 25).
Besides oxygen supply, some BPD patients with PH require 
selective pulmonary vasodilators to decrease pulmonary arterial 
pressure; these medications subsequently decrease RV afterload 
and increase cardiac output from the RV. These actions result 
in an improvement of left ventricular filling and increase of 
systemic blood pressure and coronary perfusion
26). The currently 
used medications for selective pulmonary vasodilation include 
inhaled nitric oxide (NO), inhaled prostacyclins, sildenafil, and 
endothelin-receptor antagonist. These medications can dilate the 
pulmonary artery and decrease the RV afterload through different 
mechanisms. 
Inhaled NO selectively decreases pulmonary vascular resistance 
and increases systemic venous oxygen saturation by improving 
ventilation–perfusion match
27). Inhaled NO improves oxygenation 
in infants with known BPD
28) and may be useful for long-
term treatment of pulmonary hypertension
29). Although long-
term inhaled NO treatment has been used in the BPD patients, 
especially those who require continuous mechanical ventilation, no 
study has reported such data to date. Preventive low-dose inhaled 
NO supply can reduce the incidence of BPD in the preterm infants 
with birth weight greater than 1,000 g, but it showed no effect in 
the infants with birth weight less than 1,000 g. Therefore, the use 
of preventive inhaled NO for BPD prevention is questionable
30, 31). 
Most patients require an initial inhaled NO dose of 10-20 parts per 
million (ppm) for PH treatment and a maintenance dose of 2-10 
ppm for weaning. Because sudden discontinuance of inhaled NO 
may cause rebound PH, other selective pulmonary vasodilators 
should be started before the discontinuance of inhaled NO even 
though the patient’s condition is good
32). 
Inhaled prostacyclin is less expensive and more readily available 
than inhaled NO in the centers with NICU. Aerosolized prost-
acyclin may be administered directly to the lung, and it causes 
vasodilation in the ventilated pulmonary regions; it therefore 
minimizes the systemic side effects and helps avoid catheter-
related complications in the patients
33). Inhaled iloprost is 
the representative prostacyclin derivative; it easily dissolves in 
normal saline and has a lower viscosity than other prostacyclin 
derivatives
34). The potential effect of inhaled iloprost for improving 
PH in the pediatric group has been established
35). A case study had 
reported an improvement caused by inhaled iloprost in the BPD 
patient with severe PH
36). For ensuring adequate improvement, 
inhalation should be performed 6-9 times a day because the 
half-life of the prostacyclin is extremely short. The occurrence of 
occasional bronchospasm may be a restricting factor in the use of 
inhaled prostacyclins by the BPD patients
35).
Sildenafil, a highly selective phosphodiesterase type-5 inhibitor, 
increases cyclic GMP in the pulmonary vascular smooth muscle 
cells and decreases pulmonary vascular resistance. The effect of 
sildenafil has been well proven in the patients with RV failure 
caused by PH
32). Sildenafil also has a synergistic effect with 
other pulmonary vasodilators, such as inhaled NO and inhaled 
iloprost, which have different pharmacologic mechanisms
10, 37). A 
recent study on BPD patients with PH also showed that the use 
of sildenafil was safe and provided long-term beneficial effect
38). 
The recommended starting dose of sildenafil is 0.5 mg/kg every 8 
h. If the patient shows no systemic hypotension, the dose can be 
gradually increased to get the desired effect or up to 2 mg/kg every 
6 h over 2 weeks
12). 
Endothelin-receptor antagonist inhibits the effect of endo-
thelin-1, which is a potent vasoconstrictor, and induces pulmonary 
vascular smooth muscle cell hyperplasia
12, 39). Bosentan is a 
representative non-selective endothelin-receptor antagonist that 
is orally administered. Bosentan improves exercise capacity of the 692      GB Kim •Pulmonary hypertension in infants with broncho  pulmonary dysplasia 
patients with PH by decreasing RV dilatation and by improving 
RV function and left ventricular blood filling without significant 
negative effect on systemic pressure
40, 41). Long-term randomized 
controlled studies have not been conducted in the patients with 
BPD using bosentan; however, other studies have shown that 
bosentan improved PH and functional status in daily life
6, 42). The 
recommended starting dose of bosentan is 1.5 mg/kg/L every 12 
h. If the patient shows no hepatic dysfunction after 2 weeks, the 
dose may be increased up to 3 mg/kg/d every 12 h. During the 
treatment, regular liver function tests must be conducted because 
bosentan is known to be hepatotoxic
43).
Combination therapy, which involves the simultaneous 
prescription of more than one selective PH drug, has become 
the standard treatment in many centers. Several case series have 
suggested that various drug combinations appear to be safe and 
effective
10); however, long-term safety and efficacy have not been 
evaluated in the pediatric population.
The advancements in pharmaceutical research will lead to the 
development of new selective pulmonary vasodilators in the near 
future. 
Discontinuance of medications used for treating PH in the BPD 
patients should be determined only after serial echocardiography. 
If 2 consecutive serial echocardiographic examinations reveal 
normal or near-normal findings, weaning and discontinuance of 
medication for PH may be considered
12). 
Conclusions
Because of an increase in the number of preterm infants and a 
decrease in the gestational age at birth, more patients are showing 
significant BPD and secondary PH. PH contributes significantly 
to the high morbidity and mortality in the BPD patients. To 
prevent PH and to ensure early treatment if PH is present, regular 
monitoring for PH with echocardiography and biochemical 
markers like BNP or NT-proBNP is necessary in the BPD patients 
with greater than moderate degree. In the BPD patients with 
significant PH, multi-modality treatment, including treatment for 
correcting the underlying disease, oxygen supply, the use of diverse 
selective pulmonary vasodilators, and other methods, is mandatory.
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